At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 46 enrolled
Drug / intervention
Erlotinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies
In Brief
A Phase 1 clinical trial evaluating Erlotinib and Temsirolimus for Solid Tumors. Completed, enrolled 46 participants across 1 site.
Detailed Summary
Define the maximum tolerated dose and dose limiting side-effects of temsirolimus in combination wtih erlotinib in patients with resistant solid tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2008
Enrollment StartMay 2009
Primary CompletionSep 2014
TodayJul 2026
First PostedOct 9, 2008
Enrollment StartMay 1, 2009
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 17.7 years ago
Interventions
Erlotinibdrug
Temsirolimusdrug